Comparative Pharmacology
Head-to-head clinical analysis: GYNOREST versus NORETHINDRONE ACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GYNOREST versus NORETHINDRONE ACETATE.
GYNOREST vs NORETHINDRONE ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gynorest (dydrogesterone) is a synthetic progestogen that binds to the progesterone receptor with high selectivity, inducing conformational changes that promote transcription of progesterone-responsive genes. It has no androgenic, estrogenic, or corticosteroid activity, and does not inhibit ovulation.
Progestin that suppresses gonadotropin secretion, inhibits ovulation, and induces endometrial thinning. Also binds to progesterone receptors, exerting antiestrogenic effects.
100 mg orally twice daily for 5-10 days or 300 mg orally once daily for 6-12 days.
Oral, 5 mg once daily for 14 days per cycle, beginning on day 1 of menstrual cycle; for endometriosis, 5 mg daily for 14 days then 10 mg daily for 14 days, then 15 mg daily, or as tolerated up to 15 mg daily continuous.
None Documented
None Documented
Terminal elimination half-life is approximately 16-20 hours; supports twice-daily dosing for maintenance of therapeutic levels.
Terminal elimination half-life is approximately 5-8 hours (mean 7.5 hours). Clinically, steady-state is achieved within 2-3 days of daily dosing.
Renal: 50-80% as metabolites; Fecal: 20-50% as metabolites; Biliary excretion contributes to fecal elimination.
Renal (39-61% as metabolites), biliary/fecal (35-49% as metabolites). Less than 1% excreted unchanged.
Category C
Category D/X
Progestin
Progestin